Recombinant Human CADM-140/MDA5 Protein

Catalog No.

AID00101

Description

MDA5 / IFIH1 is the CADM-140 autoantigen, involved in clinically amyopathic dermatomyositis (CADM). This is a chronic inflammatory disorder that shows typical skin manifestations of dermatomyositis but has no or little evidence of clinical myositis. Anti-CADM-140 antibodies appear to be specific to dermatomyositis, especially CADM. Patients with anti-CADM-140 antibodies frequently develop life-threatening acute progressive interstitial lung disease (ILD).

Expression system

Confidential

Species

Homo sapiens (Human)

Protein length

Confidential

Nature

Recombinant

Concentration

0.7 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Accession

Q9BYX4

Applications

As a diagnostic tool for Clinically Amyopathic Dermatomyositis (CADM).

Form

Liquid

Storage buffer

20mM Tris-HCl, pH 8.0, 100mM NaCl, 1mM DTT, 10% Glycerol.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

MDA-5, IFIH1, Helicard, Clinically amyopathic dermatomyositis autoantigen 140 kDa, Interferon-induced with helicase C domain protein 1, Helicase with 2 CARD domains, RNA helicase-DEAD box protein 116, RIG-I-like receptor 2, Interferon-induced helicase C domain-containing protein 1, MDA5, Murabutide down-regulated protein, Melanoma differentiation-associated protein 5, CADM-140 autoantigen, RH116, RLR-2

Soluble form of the MDA5 protein in human sera., PMID:38845920

IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies., PMID:37625674

Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review., PMID:37611886

Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production., PMID:35436746

Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review., PMID:35134633

Anti-MDA5 (CADM-140) positive dermatomyositis: Mucocutaneous and soft tissue manifestations., PMID:31784114

Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review., PMID:29417209

An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years., PMID:28154280

[Juvenile dermatomyositis and new autoantibodies: Cases and review]., PMID:26598044

Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis., PMID:26187000

Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody., PMID:26028648

Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms., PMID:25366013

Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility., PMID:25065441

[Case of dermatomyositis with anti-CADM-140 antibody and alveolar hemorrhage]., PMID:24943077

Detection of anti-CADM-140/MDA5 antibodies in a patient with classic dermatomyositis developing rapidly progressive interstitial lung disease., PMID:24930560

New autoantibodies and their clinical associations in juvenile myositis - a systematic review., PMID:24435027

Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis., PMID:24297126

Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis., PMID:23553518

Classification, diagnosis, and management of idiopathic inflammatory myopathies., PMID:23504386

The prognostic value of HRCT in myositis-associated interstitial lung disease., PMID:23485097

Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease., PMID:22644102

Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases., PMID:22460910

The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM., PMID:22378718

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment., PMID:22367479

Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies., PMID:22124544

[Myositis-specific autoantibodies and their clinical significance]., PMID:22068472

Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients., PMID:21883412

HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody., PMID:21632230

Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement., PMID:21532064

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study., PMID:21531040

Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study., PMID:21482889

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis., PMID:21457520

[Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody]., PMID:21384679

Cutting edge issues in polymyositis., PMID:21191666

Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls., PMID:20827201

The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody., PMID:20015976

[Myositis-specific autoantibodies]., PMID:19721478

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease., PMID:19565506

[New autoantibodies in dermatomyositis]., PMID:19457303

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression., PMID:19439503

Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis., PMID:18946327

Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions., PMID:18174673

Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance., PMID:17917530

Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis., PMID:17763420

Myositis specific autoantibodies., PMID:16901077

[Autoantibodies specifically detected in patients with polymyositis/dermatomyositis]., PMID:16651706

Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis., PMID:15880816

Document Download

Recombinant Human CADM-140/MDA5 Protein.pdf